Summary of DURB Recommendations

January 25, 2023

Meeting Date	Action Item	Status/DURB recommendation	Impact/Comments
October 2022	Addendum to calcitonin gene-related peptide (CGRP) receptor antagonist protocol	- The Board recommended the protocol	
	Proposed protocol for glucagon-like peptide-1 receptor agonists for T2D	- The Board recommended the protocol with suggestions to reword criterion #3 and removal of criterion #1 under continuation of therapy	An updated version will be presented at the next meeting
	Proposed protocol for biologics in moderate to severe asthma treatment	- The Board recommended the protocol	
	Proposed protocol for Cholbam (cholic acid)	- The Board recommended the protocol with suggestion to remove the monitoring requirement in the "continuation of therapy" section	An updated version will be presented at the next meeting
	Proposed protocol for Crysvita (burosumab-twza)	- The Board recommended the protocol	
July 2022	Addendum to calcitonin gene-related peptide (CGRP) receptor antagonist protocol	- The Board tabled the protocol with a suggestion to create a flow chart that will make it easier to understand	
	Proposed protocol for Vuity® (pilocarpine ophthalmic)	- The Board recommended the protocol with a suggestion to add optometrist to criterion #3	An updated version will be presented at the next meeting
	Proposed protocol for complement inhibitor products (Soliris®, Empaveli®, Ultomiris®)	- The Board recommended the protocol with a suggestion to follow Advisory Committee on Immunization Practices (ACIP) guidelines for determining vaccination needs for the three products	An updated version will be presented at the next meeting
	Proposed protocol for Bylvay® (odevixibat)	- The Board recommended the protocol with a suggestion to add "if able to report" to criterion #3	An updated version will be presented at the next meeting
April 2022	Proposed protocol for Hetlioz® (tasimelteon)	- The Board wanted more information about why young teens couldn't use pills and why teens and adults couldn't use the liquid	This information will be presented at the next meeting
	Proposed protocol for cysteamine products (Cystagon® and Procysbi®)	- The Board recommended the protocol	
	Proposed protocol for Revcovi® (elapegademase)	- The Board recommended the protocol	
	Proposed protocol for Luxturna® (voretigene neparvovec-rzyl)	- The Board recommended the protocol	

Summary of DURB Recommendations

Meeting Date	Action Item	Status/DURB recommendation	Impact/Comments
January 2022	Addendum for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor products protocol	- The Board recommended the addendum to the protocol	
	Addendum for Spravato® (esketamine) protocol	- The Board recommended the addendum to the protocol	
	Proposed protocol for Gamifant® (emapalumab-lzsg)	- The Board recommended the protocol with a suggestion to change criterion #1 to emphasize "primary" HLH	An updated version was presented and approved at the following meeting.
	Proposed protocol for nitisinone products	- The Board recommended the protocol with suggestions to reword criteria #4 and #6	An updated version was presented and approved at the following meeting.
	Proposed protocol for Lucemyra® (lofexidine)	- The Board recommended the protocol with suggestions to criterion #4 and delete criterion #5	An updated version was presented and approved at the following meeting.
	Proposed protocol for Paxlovid® (nirmatrelvir/ritonavir)	- The Board approved the protocol	
	Proposed protocol for molnupiravir	- The Board approved the protocol	